Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

Objective To investigate whether angiotensin receptor blockers protect against Alzheimer’s disease and dementia or reduce the progression of both diseases. Design Prospective cohort analysis. Setting Administrative database of the US Veteran Affairs, 2002-6. Population 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease. Main outcome measures Time to incident Alzheimer’s disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the “cardiovascular comparator”) over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer’s disease or dementia. Results Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer’s disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer’s disease. Conclusions Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer’s disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.

[1]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[2]  J. Goch,et al.  Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study , 2008, Journal of hypertension.

[3]  K. Chopra,et al.  Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory , 1998, Neuropeptides.

[4]  M. Albert,et al.  Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease , 1994, Neurology.

[5]  Wei Zhao,et al.  Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. , 2007, The Journal of clinical investigation.

[6]  L S Honig,et al.  Aggregation of vascular risk factors and risk of incident Alzheimer disease , 2005, Neurology.

[7]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[8]  P. Rosenstiel,et al.  The Angiotensin II Type 2 (AT2) Receptor Promotes Axonal Regeneration in the Optic Nerve of Adult Rats , 1998, The Journal of experimental medicine.

[9]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[10]  M. Paul,et al.  The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. , 1995, The Journal of clinical investigation.

[11]  L. Tavazzi,et al.  Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. , 2005, Journal of cardiac failure.

[12]  K. Niwa,et al.  Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression , 2004, Neurology.

[13]  M. Mogi,et al.  Cognitive Deficit in Amyloid-&bgr;–Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-&ggr; Activation , 2009, Hypertension.

[14]  L. Kappelle,et al.  Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? , 2005, Biochemical Society transactions.

[15]  P. Zandi,et al.  Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. , 2006, Archives of neurology.

[16]  D. Iarussi,et al.  Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. , 1999, American journal of hypertension.

[17]  Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study , 2007, Cardiovascular diabetology.

[18]  H. Fillit,et al.  Cardiovascular disease risk factors and cognitive impairment. , 2006, The American journal of cardiology.

[19]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[20]  G. Deuschl,et al.  Neuroprotection with Angiotensin Receptor Antagonists , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[21]  T. Ogihara,et al.  Angiotensin Receptor Blocker Prevented &bgr;-Amyloid–Induced Cognitive Impairment Associated With Recovery of Neurovascular Coupling , 2009, Hypertension.

[22]  J. J. Claus,et al.  Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study , 1994, BMJ.

[23]  G. Samsa,et al.  Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension , 2008, Annals of Internal Medicine.

[24]  I. Poon.  Effects of Antihypertensive Drug Treatment on the Risk of Dementia and Cognitive Impairment , 2008, Pharmacotherapy.

[25]  J. C. de la Torre,et al.  For Personal Use. Only Reproduce with Permission the Lancet Publishing Group. Personal View Is Ad Neurodegenerative or Vascular? Is Ad Neurodegenerative? Is Alzheimer's Disease a Neurodegenerative or a Vascular Disorder? Data, Dogma, and Dialectics , 2022 .

[26]  A. Villringer,et al.  Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats , 2008, Journal of hypertension.

[27]  R. Havlik,et al.  Midlife blood pressure and dementia: the Honolulu–Asia aging study☆ , 2000, Neurobiology of Aging.

[28]  J. C. Torre.  Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[29]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[30]  P. Kehoe,et al.  Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease? , 2007, The Lancet Neurology.

[31]  Abu T. M. Serajuddin,et al.  Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (ACE) Inhibitors , 1992, Pharmaceutical Research.

[32]  Hilkka Soininen,et al.  Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.

[33]  A. Hofman,et al.  Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.

[34]  David L. Brown,et al.  Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). , 2007, The American journal of cardiology.

[35]  Use of Antidepressant Medications: Are There Differences in Psychiatric Visits Among Patient Treatments in the Veterans Administration? , 2004, Medical care.

[36]  A. Barabash,et al.  Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[38]  T. Herdegen,et al.  Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. , 1998, Brain research. Molecular brain research.

[39]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[40]  E. Stallard,et al.  Projected use of long-term-care services by enrolled Veterans. , 2007, The Gerontologist.

[41]  M. Albert,et al.  Predicting time to nursing home care and death in individuals with Alzheimer disease. , 1997, JAMA.

[42]  Constantine Lyketsos,et al.  Dementia and Alzheimer's Disease Incidence in Relationship to Cardiovascular Disease in the Cardiovascular Health Study Cohort , 2005, Journal of the American Geriatrics Society.

[43]  H. Sackeim,et al.  Cerebral perfusion as a diagnostic marker of early Alzheimer's disease , 1988, Neurology.

[44]  R. Fogari,et al.  Influence of losartan and atenolol on memory function in very elderly hypertensive patients , 2003, Journal of Human Hypertension.

[45]  T. Unger,et al.  Angiotensin receptor blockers and cerebral protection in stroke , 2006, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[46]  David A. Calhoun,et al.  Drugs targeting the renin–angiotensin–aldosterone system , 2002, Nature Reviews Drug Discovery.

[47]  A. Hofman,et al.  Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) , 2005, Alzheimer's & Dementia.

[48]  D. Cornfield,et al.  A beta-peptides enhance vasoconstriction in cerebral circulation. , 2001, American journal of physiology. Heart and circulatory physiology.

[49]  D. Cornfield,et al.  Aβ-peptides enhance vasoconstriction in cerebral circulation , 2001 .

[50]  K. Chopra,et al.  Comparative studies on the memory- enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm , 2001, Neuropeptides.

[51]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[52]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[53]  T. Ichiki,et al.  ANGIOTENSIN RECEPTORS: MOLECULAR BIOLOGY AND SIGNALLING , 1999, Clinical and experimental pharmacology & physiology.

[54]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[55]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[56]  P. Zandi,et al.  Cholesterol and Alzheimer's disease—is there a relation? , 2006, Mechanisms of Ageing and Development.

[57]  S. Love,et al.  Angiotensins in Alzheimer's disease – friend or foe? , 2009, Trends in Neurosciences.

[58]  D. Geldmacher,et al.  Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.

[59]  The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease. , 1996, Journal of biopharmaceutical statistics.

[60]  A. Hofman,et al.  Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study , 2005, Annals of neurology.

[61]  M. Trabucchi,et al.  Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment , 2006, International journal of geriatric psychiatry.

[62]  G. Joseph,et al.  Pharmacy Data in the VA Health Care System , 2003, Medical care research and review : MCRR.